Benzo five-membered unsaturated heterocycle compound and preparation method thereof

Abstract

The invention provides a benzo five-membered unsaturated heterocycle compound and a preparation method thereof. The compound has the structure shown in the general formula (I). A test shows that the compound has the activity for up regulating the bone morphogenetic protein BMP-2 expression and the function of resisting osteoporosis. The invention also provides a medicine composition containing the compound as the active ingredient. An in-vitro activity test shows that the compound represents obvious up-regulating function for the bone morphogenetic protein BMP-2 expression; and an SAMP6 rapidageing mice in-vivo activity test result shows that the compound has the function of improving the osteoporosis of ageing model mice. The invention provides a basis for further research and development of the osteoporosis-resisting medicine of the compound.

Description

technical field The present invention relates to a class of benzo five-membered unsaturated heterocyclic compounds, and discloses a preparation method of the benzo five-membered unsaturated heterocyclic compounds. The present invention also relates to the benzo five-membered unsaturated heterocyclic compounds The application in anti-osteoporosis and the pharmaceutical composition containing the compound as an active component. Background technique Osteoporosis is a common disease worldwide, which mainly occurs in middle-aged and elderly people, especially menopausal women. The main clinical feature is systemic osteopenia with destruction of bone tissue microarchitecture. People with osteoporosis have a significantly increased risk of fractures, especially injuries to the wrist, spine, and hip. It is estimated that 30-50% of women and 15-30% of men with osteoporosis will experience a fracture in their lifetime. Hospital stays for patients with fractures exceeded those for p...

AI Technical Summary

Problems solved by technology

In Germany, the cost of an injection of recombinant human BMP-2 protein in the treatment of tibial fractures is about 2970 euros, and the use of this drug cannot be reimbursed by health insurance companies

Therefore, the use of recombinant human BMP-2 protein will bring a heavy economic burden to patients

Images